Risk Factors ID'd for Monoclonal Gammopathy of Undetermined Significance
19 Jan 2024
Clinical Result
FRIDAY, Jan. 19, 2024 -- For individuals at increased risk for multiple myeloma, risk factors associated with mass spectrometry (MS) monoclonal gammopathy of undetermined significance (MGUS) include obesity, heavy smoking, and short sleep duration, according to a study published online Jan. 11 in Blood Advances.
David J. Lee, M.D., from Massachusetts General Hospital in Boston, and colleagues enrolled 2,628 individuals at elevated risk for multiple myeloma who were screened by MS to examine the associations between exposures and MS outcomes. Those with monoclonal proteins with concentrations ≥0.2 g/L were classified as MS-MGUS.
The researchers found that after adjustment for age, sex, Black race, education, and income, obesity was associated with MS-MGUS compared with normal weight (odds ratio, 1.73). A reduced likelihood of MS-MGUS was seen with high physical activity (≥73.5 versus 30 pack-years versus never smoker: odds ratio, 2.19) and short sleep (sleep less than six versus six or more hours/day: odds ratio, 2.11).
"These results guide our future research in understanding the influence of modifiable risk factors, such as weight, exercise, and smoking, on cancer risk," Lee said in a statement. "Before we can develop effective preventative health strategies to lower the risk of serious diseases like multiple myeloma, we first need to better understand the relationship between MGUS and potentially modifiable risk factors like obesity."
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.